Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors
Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.
Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.